The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
cataloging the success, the huge waterfall event in the immunotherapy development era when PD-1, PD-L1 interactions were... discovered and then leveraged as a therapeutic. That fraction of cancer patients who are one drug away from clearing their tumor with a P1 antibody, which is the largest impact we've had with an immunotherapy of any kind by a long shot in terms of numbers of patients helped.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
half of that Advance has come from one therapeutic modality pd1 antibody based immunotherapy a single approach um has accounted for half that number it's astounding
so pd1 is doing really you know the the heavy lifting
Whole-body MRI screening in healthy adults produces more incidentaloma harm than cancer-mortality benefit.
Starting colonoscopy screening at 45 (vs 50) prevents enough early-onset cancers to justify the population cost.
Multi-cancer liquid-biopsy tests like Galleri detect early cancers at a stage that meaningfully improves survival.